97077-43-5

Usage

Classification

Potent synthetic hallucinogen

Drug class

Phenethylamine

Derivative of

2C-I

Effects

Intense visual and auditory hallucinogenic effects

Method of use

Often sold on blotter paper and ingested orally, can also be snorted or smoked

Potential for abuse

High

Side effects

Seizures, cardiac arrest, and psychotic episodes

Risk

Often sold in counterfeit form as LSD, making it difficult for users to know the actual substance they are ingesting

Legal status

Schedule I controlled substance in the United States.

Upstream product

• 59283-35-1 5-methoxy-2-methyl-1-(phenylmethyl)-1H-indol-3-ylacetic acid 
• 57-13-6 urea 
• 163734-57-4 5-methoxy-2-methyl-1-(phenylmethyl)-1H-indole-3-acetic acid hydrazide 
• 60011-55-4 3-(cyanomethyl)-2-methyl-1-(phenylmethyl)-5-methoxyindole 
• 15992-10-6 2-(5-methoxy-2-methyl-1H-indol-3-yl)acetamide 
• 100-44-7 benzyl chloride 
• 123-76-2 levulinic acid 
• 624-45-3 levulinic acid methyl ester 
• 3471-32-7 4-Methoxyphenylhydrazine 
• 5705-10-2 N-benzyl-N-(4-methoxy-phenyl)-hydrazine; hydrochloride 
• 17536-38-8 ethyl 2-(5-methoxy-2-methyl-1H-indol-3-yl)acetate 
• 94918-24-8 5-methoxy-2-methyl-1-(phenylmethyl)-1H-indole-3-acetic acid ethyl ester 
• 19501-58-7 4-methoxyphenylhydrazine hydrochloride 
• 106-51-4 p-benzoquinone 

Downstream Products

• 441-91-8 2-(1-benzyl-5-methoxy-2-methyl-indol-3-yl)-ethylamine 
• 164084-24-6 3-(amidomethyl)-2-methyl-1-(phenylmethyl)-5-hydroxyindole 
• 185501-12-6 2-[1-Benzyl-5-(3-cyano-propoxy)-2-methyl-1H-indol-3-yl]-acetamide 
• 164084-18-8 2-[[[3-(2-amino-2-oxoethyl)-2-methyl-1-(phenylmethyl)-1H-indol-5-yl]oxy]methyl]benzoic acid methyl ester 
• 164084-22-4 3-[[[3-(2-amino-2-oxoethyl)-2-methyl-1-(phenylmethyl)-1H-indol-5-yl]oxy]methyl]benzoic acid methyl ester 
• 185500-96-3 3-(1-Benzyl-3-carbamoylmethyl-2-methyl-1H-indol-5-yloxy)-benzoic acid ethyl ester 

Relevant academic research and scientific papers

Indole-5-phenylcarbamate derivatives as human non-pancreatic secretory phospholipase A2 inhibitor

The synthesis of the human non-pancreatic secretory phospholipase A2 inhibitor (IC50 = 1.81 ± 0.59 μM) is reported.

Synthesis of indomethacin analogues for evaluation as modulators of MRP activity

Synthesis of a range of indomethacin analogues, required for investigation in combination toxicity assays, bearing both N-benzyl and N-benzoyl groups, is described. Copyright

1H-INDOLE-3-ACETAMIDE SPLA2 INHIBITORS

A class of novel 1-indole-3-acetamides represented by the formula; is disclosed together with the use of such indole compounds for inhibiting sPLA2 mediated release of fatty acids.

Indole inhibitors of human nonpancreatic secretory phospholipase A2. 1. Indole-3-acetamides

Phospholipases (PLAs) produce rate-limiting precursors in the biosynthesis of various types of biologically active lipids involved in inflammatory processes. Increased levels of human nonpancreatic secretory phospholipase A2 (hnps-PLA2) have been detected in several pathological conditions. An inhibitor of this enzyme could have therapeutic utility. A broad screening program was carried out to identify chemical structures which could inhibit hnps-PLA2. One of the lead compounds generated by the screening program was 5-methoxy-2-methyl-1-(phenylmethyl)-1H-indole-3-acetic acid (13a). We describe the syntheses, structure-activity relationships, and pharmacological activities of a series of indole-3-acetamides and related compounds derived from this lead. This SAR was undertaken with the aid of X- ray crystal structures of complexes between the inhibitors and hnps-PLA2 which were of great value in directing the SAR.